Clinical Edge Journal Scan

Psoriatic arthritis: An independent risk factor for reduced bone density and fractures


 

Key clinical point: Regular assessment of bone mineral density and initiation of primary prevention should be considered in patients with psoriatic arthritis (PsA) as they are predisposed to falls and fractures because of reduced bone density, particularly those with late-onset psoriasis involving scalp.

Major finding: Patients with PsA were at a significantly higher risk for osteopenia or osteoporosis (odds ratio [OR] 21.9; CI 7.1-67.7) and prevalent fractures (OR 3.42; P = .002) compared with control individuals, with scalp involvement ( P = .0049) and late onset of psoriasis ( P = .029) being significantly associated with greater number of prevalent fractures.

Study details: Findings are from an observational cohort study including 61 patients with PsA and 69 age-matched control individuals.

Disclosures: This study did not report the source of funding. The authors reported no conflicts of interest.

Source: Halasi A et al. Psoriatic arthritis and its special features predispose not only for osteoporosis but also for fractures and falls. J Dermatol. 2023 (Jan 17). Doi: 10.1111/1346-8138.16710

Recommended Reading

Circulating microRNA can differentiate between psoriasis and psoriatic arthritis
Psoriatic Arthritis ICYMI
Baseline cardiovascular risk may influence MACE and malignancy incidences in tofacitinib-treated PsA patients
Psoriatic Arthritis ICYMI
Long-term safety and tolerability of upadacitinib in PsA
Psoriatic Arthritis ICYMI
PsA: Baseline disease activity predicts DAPSA response in patients treated with apremilast
Psoriatic Arthritis ICYMI
PsA prediction tool approaches clinical utility
Psoriatic Arthritis ICYMI
Are repeat radiographs necessary in rheumatoid and psoriatic arthritis?
Psoriatic Arthritis ICYMI
What’s holding back physicians from prescribing biosimilars? Four specialties weigh in
Psoriatic Arthritis ICYMI
Isolated nail psoriasis may bring arthritis into play
Psoriatic Arthritis ICYMI
Commentary: Concerning PsA treatments and comorbidities, March 2023
Psoriatic Arthritis ICYMI
PsA: Guselkumab demonstrates consistent safety profile irrespective of prior TNFi exposure
Psoriatic Arthritis ICYMI